ALK and non-small cell lung carcinoma: When the cell models exist (for example, H2228 cell line representing EML4-ALK rearranged non-small cell lung cancer (NSCLC), which occurs in ∼5% of NSCLC), preclinical studies using such cell lines have helped to identify therapeutic targets and accelerated clinical testing25, 26.